Related Experiment Video

Updated: Mar 20, 2026

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.8K

Inhibitors of Angiogenesis

H Büning1, U T Hacker2

  • 1Institute of Experimental Hematology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. buening.hildegard@mh-hannover.de.

Advances in Experimental Medicine and Biology
|May 30, 2016
PubMed

Insights

Anti-angiogenic therapies target blood vessel formation, crucial in diseases like cancer and macular degeneration. This review covers protein/receptor blockade strategies and gene therapy for therapeutic angiogenesis inhibition.

Area of Science:

  • Molecular biology and therapeutic strategies.
  • Focus on angiogenesis and its therapeutic manipulation.

Background:

  • Angiogenesis, or new blood vessel formation, is critical in various diseases including cancer, ischemia, and inflammatory conditions.
  • Understanding the molecular mechanisms of angiogenesis has enabled the development of targeted therapies.

Purpose of the Study:

  • To review anti-angiogenic therapies for clinical applications.
  • To outline strategies targeting angiogenic proteins and receptors.
  • To present gene therapy approaches for anti-angiogenesis.

Main Methods:

  • Review of preclinical and clinical data on anti-angiogenic strategies.
  • Focus on blockade of angiogenic proteins and receptors.
  • Inclusion of gene therapy-based anti-angiogenic methods.

Main Results:

  • Anti-angiogenic therapies are established treatments for cancers and neovascular age-related macular degeneration.
  • Strategies involving blockade of angiogenic factors and their receptors show therapeutic potential.
  • Gene therapy offers novel approaches to inhibit angiogenesis.

Conclusions:

  • Targeting angiogenesis is a validated therapeutic principle.
  • Further development of anti-angiogenic strategies, including gene therapy, holds promise for treating angiogenesis-dependent diseases.
  • Comprehensive understanding of angiogenic pathways is key to successful therapeutic interventions.
Keywords:
AngiogenesisAntibodiesGene therapyVEGFVascular maturation

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

10.2K
Retinal Explant of the Adult Mouse Retina as an Ex Vivo Model for Studying Retinal Neurovascular Diseases06:51

Retinal Explant of the Adult Mouse Retina as an Ex Vivo Model for Studying Retinal Neurovascular Diseases

Published on: December 9, 2022

5.5K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K